Results 71 to 80 of about 3,657 (192)

Delamanid [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

The experience of using delamanid in the Chechen Republic

Tuberculosis and Lung Diseases, 2020
.
S. M. Lorsanov, Z. B. Khaydarkhanova, S. B. Khunkarsultanov   +2 more
openaire   +3 more sources

Synthesis, Antimycobacterial Activity, and Computational Insight of Novel 1,4‐Benzoxazin‐2‐one Derivatives as Promising Candidates against Multidrug‐Resistant Mycobacterium Tuberculosis

ChemMedChem, Volume 20, Issue 14, July 18, 2025.
A series of 14 novel 1,4‐benzoxazinone derivatives is tested against various strains of Mycobacterium tuberculosis. All compounds show high activity against all tested strains, particularly the resistant strains. Additionally, the novel derivatives exhibit low cytotoxicity toward mammalian Vero cells.
Maria Grazia Mamolo, Emanuele Carosati, Diletta Pasin, Alessandro De Logu, Gianluigi Cabiddu, Marko Jukič, Daniele Zampieri   +6 more
wiley   +1 more source

Is Mycobacterial InhA a Suitable Target for Rational Drug Design?

ChemMedChem, Volume 20, Issue 13, July 1, 2025.
InhA is the target of isoniazid, a first‐line antituberculosis drug. Isoniazid is, in fact, a prodrug that needs to be activated. Researchers are trying to develop direct inhibitors of InhA. This includes the resolution of crystallographic structures. The Protein Data Bank contains over a hundred InhA structures.
Julien Rizet, Laurent Maveyraud, David Rengel, Valérie Guillet, Gabriel Publicola, Frédéric Rodriguez, Christian Lherbet, Lionel Mourey   +7 more
wiley   +1 more source

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]

, 2015
Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infection and Drug Resistance. 2015;8:359–366. Dr Rustomjee and Professor Zumla are grateful to a reader for raising some issues regarding ...
Zumla A, Rustomjee R
core  

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Emerging Infectious Diseases, 2017
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency.
Andrey Maryandyshev, Emanuele Pontali, Simon Tiberi, Onno Akkerman, Shashank Ganatra, Tsetan Dorji Sadutshang, Jan-Willem Alffenaar, Rohit Amale, Jai Mullerpattan, Sonam Topgyal, Zarir Farokh Udwadia, Rosella Centis, Lia D’Ambrosio, Giovanni Sotgiu, Giovanni Battista Migliori   +14 more
doaj   +1 more source

Machine Learning‐Based High‐Throughput Screening, Molecular Modeling and Quantum Chemical Analysis to Investigate Mycobacterium tuberculosis MetRS Inhibitors

ChemistryOpen, Volume 14, Issue 7, July 2025.
This paper provides a comprehensive approach using the ChEMBL database to construct a machine learning model that screened 10 million compounds from the eMolecules database. Two promising inhibitors targeting Mycobacterium tuberculosis methionyl‐tRNA synthetase were identified.
Rajesh Maharjan, Kalpana Gyawali, Arjun Acharya, Madan Khanal, Kamal Khanal, Mohan Bahadur Kshetri, Madhav Prasad Ghimire, Tika Ram Lamichhane   +7 more
wiley   +1 more source

Flowchart of patients eligible for the comparative effectiveness of delamanid analysis in the endTB observational cohort.

, 2023
Flowchart of patients eligible for the comparative effectiveness of delamanid analysis in the endTB observational cohort.
Zaw Myint (6166169), Samreen Sarfaraz (10884833), Kwonjune J. Seung (15374272), Stalz Charles Vilbrun (15374290), Sara Lodi (462540), Carole D. Mitnick (8385144), Michael Rich (363365), Munara Gulanbaeva (15374308), Jay Achar (3405698), Palwasha Khan (771358), Saman Ahmed (15374296), Mathieu Bastard (109538), Marika Gergedava (15374311), Catherine Hewison (7293095), Elena Algozhina (15374299), Carly A. Rodriguez (2805904), Stephanie Mpinda (15374281), Naseem Salahuddin (496353), Kalkidan Yae (15374293), Cut Yulia Indah Sari (15374314), Nara Melikyan (15374278), Ofelya Petrosyan (15374287), Sara de Guadelupe Perea Moreno (15374305), Yugandran Naidoo (15374284), Jude Beauchamp (15374302), Helena Huerga (109527), Uzma Khan (583489), Sidney Atwood (496123), Molly F. Franke (7372517), C. Robert Horsburgh (7512506), Md Manzur-ul-Alam (15374275)   +30 more
core   +1 more source

Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India

Lung India
Aim: To determine the bacteriological conversion rate after 6 months of Delamanid (DLM) based treatment in children with drug-resistant tuberculosis (DR-TB) and determine factors associated with bacteriological conversion.
Dhruv Kalawadia, Darshini Gandhi, Tsering Y Dirkhipa, Akanksha Jaiswal, Daksha Shah, Jyoti Salve, Malik Parmar, Kuldeep S Sachdeva, Minnie Bodhanwala, Ira Shah   +9 more
doaj   +1 more source

Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis

, 2017
Tuberculosis (TB) treatment is long and requires multiple drugs, likely due to various phenotypes of TB bacilli with variable drug susceptibilities. Drugs with broad activity are urgently needed.
Hiroyuki Hashizume, Tatsuo Tomishige, Ryuki Kitamoto, Mamoru Fujiwara, Yoshio Ohba, Izuru Nakamura, Makoto Matsumoto, Xiuhao Chen, Erina Hanaki, Miki Matsuba   +9 more
core   +1 more source